Myriad Announces Important New Data for Its EndoPredict® Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium

World News: . []

SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that new data on its EndoPredict test will be presented by academic collaborators at the San Antonio Breast Cancer Symposium.  The key findings are that EndoPredict accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjunctive chemotherapy at the time of diagnosis and who is unlikely to benefit from extended endocrine therapy five years after diagnosis.  The EndoPredict test was recently included in The for breast cancer.  

“Women with breast cancer, and the clinicians caring for them, will benefit from a single comprehensive solution to answer critical clinical questions about long-term prognosis, the need for adjuvant chemotherapy and the need for extended endocrine therapy,” said Johnathan Lancaster, M.D., Ph.D., gynecologic oncologist and chief medical officer, Myriad Genetics.  “The new data we are presenting at SABCS demonstrate that EndoPredict is the only test that answers all three questions, enabling precision care and better health outcomes for women battling breast cancer.”“These important studies highlight scientific advances that are foundational to a new generation of breast cancer precision medicine tools; one genetic test, providing multiple clinical answers,” said Hatem Soliman, M.D., medical oncologist, Center for Women’s Oncology, Moffitt Cancer Center.  “We should collectively utilize these new technologies to help inform our treatment decisions and improve the quality of life for our patients.”The key data being presented at SABCS are summarized below.  Please visit Myriad at Booth #1001 to learn more about genetic testing for breast cancer.  Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news and updates by using the hashtag #SABCS18.

This retrospective analysis of five prospective studies evaluated whether EndoPredict (EPclin) can predict the chemotherapy benefit in 3,746 women with ER-positive, HER2-negative breast cancer who have received five years of endocrine therapy (ET) alone or in combination with chemotherapy (ET+C).  The primary endpoint was the 10-year distant recurrence free interval (DRFI).The results demonstrated that patients with a high (>3.3) EndoPredict score on ET+C had a significantly lower 10-year DR risk than those on ET alone (Graph 1).  In contrast, there were no significant differences in the 10-year DR between ET and ET+C for patients with low (<3.3) EndoPredict Scores (Graph 1).  These findings were statistically significant (p=0.02) and confirm that EndoPredict was able to accurately predict chemotherapy benefit in women with ER-positive, HER2-negative breast cancer.

A graph accompanying this announcement is available at

“In this study with contemporary chemotherapy regimens, patients with a high EndoPredict test score who received endocrine therapy plus chemotherapy had significantly better outcomes than those receiving endocrine therapy alone,” said Ivana Sestak, Ph.D., principal investigator, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London.  “Based on these findings, EndoPredict may be used in the decision-making process about adjunctive chemotherapy.”

This study assessed the ability of the EndoPredict (EPclin) test to predict early distant recurrence (0-10 years) and late recurrence (5-15 years) of breast cancer, according to nodal status.  The analysis included 1,702 patients with ER-positive, HER2-negative breast cancer who received five years of endocrine therapy alone.  Overall, 62.2 percent of patients had low EndoPredict scores.The results demonstrated that EndoPredict is highly predictive of both early and late distant recurrence (DR), regardless of nodal status.  Women with low EndoPredict scores had statistically significantly reduced risk compared to those with high scores (Table 1). 

            “In this study, women with a high EndoPredict score were four times more likely to experience a breast cancer recurrence setback,” said Martin Filipits, Ph.D., principal investigator, Institute of Cancer Research, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna Head of ABCSG Research.  “Importantly, the low risk group had a 4 percent rate of distant recurrence in years 5-15 compared to 16 percent in the high risk group, which suggests that EndoPredict can help select patients who can safely forgo extended endocrine therapy beyond five years.”

Media Contact:  Ron Rogers                          Investor Contact:        Scott Gleason                          (801) 584-3065                                                        (801) 584-1143                                                                        

More news and information about Myriad Genetics, Inc.

Published By:

Globe Newswire: 13:30 GMT Friday 7th December 2018

Published: .

Search for other references to "myriad" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us